The United States JE (Japanese Encephalitis) vaccine market was valued at USD 31.87 Million in 2025 and is expected to grow at a CAGR of 4.50%, reaching USD 49.49 Million by 2035. The market growth is driven by rising travel‐related demand, enhanced vaccine adoption, and public health policy commitments.
Base Year
Historical Period
Forecast Period
The growing international travel and military deployment have increased the demand for Japanese Encephalitis vaccines in the United States.
Advancements in vaccine technology, including mRNA platforms, are expected to accelerate product approvals and market expansion.
Government contracts and public health initiatives boost vaccine availability, strengthening the market outlook.
Compound Annual Growth Rate
4.5%
Value in USD Million
2026-2035
*this image is indicative*
Japanese encephalitis (JE) is a rare but serious viral infection in the United States, primarily affecting travelers and military personnel returning from endemic regions in Asia. The U.S. Centers for Disease Control and Prevention (CDC) recommends the JE vaccine for individuals traveling to areas with active transmission. The availability of the IXIARO® vaccine, approved for use in individuals aged 2 months and older, supports preventive measures against this disease.
Government Contracts and Rising Travel Drive JE Vaccine Market Growth
The increasing travel to endemic regions and rising awareness about mosquito-borne diseases are key drivers boosting the U.S. Japanese Encephalitis (JE) vaccine market. For instance, in February 2025, Valneva recently secured a USD 33 million contract to supply its JE vaccine to the U.S. government, aiming to protect military personnel and travelers. This deal highlights growing government commitment to vaccine availability, which is expected to accelerate market growth and strengthen vaccine adoption throughout the forecast period.
Key market trends include rising JE cases linked to travel and increased FDA support for innovative vaccines.
Rising Incidence and Travel Risks Fuel U.S. JE (Japanese Encephalitis) Vaccine Market Growth
As per the Benton County Mosquito Control, Japanese encephalitis remains the leading cause of viral encephalitis in Asia, with 30,000 to 50,000 annual cases reported. Although cases in the U.S. are rare, primarily among travelers and military personnel in Asia, occasional outbreaks in U.S. territories in the Western Pacific highlight ongoing risk. This underlines the importance of continued vaccine development and awareness, driving steady growth and demand in the vaccine market.
Single-Dose Injection to Lead the Market Share by Dose Type
The single-dose injection segment is likely to hold the largest market share due to its convenience and better patient compliance. Single-dose vaccines simplify administration, reduce healthcare visits, and lower the risk of dosing errors, making them preferable for travellers and military personnel. Although multi-dose injections may offer cost advantages, the demand for quick, effective protection strongly drives the preference for single-dose options in this market.
The New England region is likely to hold the largest market share due to its high concentration of international travelers and advanced healthcare infrastructure supporting vaccine distribution. The Far West follows closely, with major ports and military bases increasing demand. The Southeast and Southwest, with their warmer climates, face higher mosquito activity, prompting preventive vaccination programs. Other regions like the Great Lakes and Rocky Mountain show moderate growth, while the Plains and Mideast remain smaller markets due to lower travel-related exposure.
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. Established in 2013 through the merger of Intercell AG and Vivalis SA, Valneva focuses on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. The company markets three proprietary travel vaccines: IXIARO® for Japanese encephalitis, DUKORAL® for cholera and ETEC, and IXCHIQ® for chikungunya. Valneva's pipeline includes candidates for Lyme disease, Shigella, and Zika virus.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Dose Type
Market Breakup by Age Group
Market Breakup by Region
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Dose Type |
|
| Breakup by Age Group |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share